Key Points Bristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation. Investors remain uncertain about the company's efforts to replace legacy drug sales with the sale of new drug products. This uncertainty could work in your favor, as Bristol Myers Squibb shares could re-rate if the turnaround generates further financial improvement. 10 stocks we like better than Bristol Myers Squibb › Over the past year, Bristol Myers Squibb (NYSE: BMY) shares surged around 42.5%. Yet even after this strong performance, shares remain at the low end of the company's long-term valuation range.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.